Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care: the Eurobact II Multinational Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Outcome Rea
- 入组人数
- 3,058
- 试验地点
- 2
- 主要终点
- Mortality
研究概览
简要总结
Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.
详细描述
Eurobact II is a multinational multicentre cohort study that will include patients with hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is designed to investigate the effects of HA-BSI on mortality at day 28. To describe the determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the microorganism, the characteristics of antimicrobial therapy and of source control. It will investigate patient specific and organizational factors and will describe the determinants of management of HA-BSI in ICUs.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 Years.
- •Hospital Acquired Bloodstream Infection (HA-BSI).
- •Treated in the ICU.
- •ICU acquired OR
- •Hospital acquired prior to ICU admission
排除标准
- •Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI.
- •Previous inclusion in the study.
- •HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours following hospital admission.
结局指标
主要结局
Mortality
时间窗: 28 days
Vital status
次要结局
- Clinical cure(7 days, 28 days)
- Days free or organ supportive therapy(28 days)
- Microbiological cure(7 days, 28 days)
- Progress of organ failures(7 days)